A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants

• ClinicalTrials.gov Identifier: NCT04722562
• Recruitment Status: Completed
• First Posted: January 25, 2021
• Last Update Posted: January 25, 2021
• Sponsor: Bayer
• Collaborator: Merck Sharp & Dohme Corp.
• Information provided by (Responsible Party): Bayer

Study Description

Brief Summary:

Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body. Liver impairment which co-occurs in patients with heart failure is a common condition in which the liver is not removing the drugs from the blood as well as it should.

The goal of the study was to learn more about the safety of vericiguat (BAY1021189), how it was tolerated and the way the body absorbed, distributed and excreted the study dug given as a single oral dose of 2.5 mg tablet in participants with liver impairment and healthy participants matched for age-, gender-, and weight.

The participants stayed at the trial site for about 5 days. During this time, the doctors took blood and urine samples and checked the participants' health. About 7 after the participants took vericiguat (BAY1021189), the researchers checked the participants' health again and asked about any medical problems they had.

Condition or disease	Intervention/treatment	Phase
Heart Failure	Drug: Vericiguat (BAY1021189)	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 27 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Investigation of the Pharmacokinetics, Safety, and Tolerability of Vericiguat (BAY1021189) in Subjects With Hepatic Impairment (Classified as Child Pugh A or B) and in Age-, Weight-, and Gender-matched Healthy Subjects Following a Single Oral Dose in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
• Actual Study Start Date: July 16, 2014
• Actual Primary Completion Date: January 21, 2015
• Actual Study Completion Date: April 30, 2015

Arms and Interventions

Arm	Intervention/treatment
Experimental: Child Pugh A; Participants with mild hepatic impairment	Drug: Vericiguat (BAY1021189); Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Experimental: Child Pugh B; Participants with moderate hepatic impairment	Drug: Vericiguat (BAY1021189); Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)
Experimental: Healthy participants; Participants with normal hepatic function	Drug: Vericiguat (BAY1021189); Oral single dose of 2.5 mg (2 x 1.25 mg immediate release tablet)

Outcome Measures

Primary Outcome Measures :

1. AUC of vericiguat [ Time Frame: Up to 96 hours ]
   Area under the concentration vs. time curve from zero to infinity after single dose administration
2. AUCu of vericiguat [ Time Frame: Up to 96 hours ]
   AUC unbound
3. Cmax of vericiguat [ Time Frame: Up to 96 hours ]
   Maximum observed drug concentration in measured matrix after single dose administration
4. Cmax,u of vericiguat [ Time Frame: Up to 96 hours ]
   Cmax unbound

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 79 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

For all subjects:

• Aged between 18 and 79 years (inclusive) with body mass index 18 to 34 kg/m^2 (both inclusive)
• Women without childbearing potential; women of childbearing potential only if the pregnancy test was negative and a combination of condoms with a safe and highly effective

For subjects with hepatic impairment:

• Subjects with documented liver cirrhosis confirmed by histopathology, e.g., previous liver biopsy, laparoscopy, ultrasound, or fibroscan
• Subjects with hepatic impairment (Child Pugh A or B)
• Subjects with stable liver disease in the last 2 months

For healthy subjects:

• Mean age and body weight in the control group and in the two groups with hepatic impairment (Child Pugh A and B) should not vary by more than ± 10 years and ± 10 kg
• Gender matched

Exclusion Criteria:

For all subjects:

• Subjects with a medical disorder, condition, or history of such that would impair the subject's ability to participate or complete this study in the opinion of the investigator or the sponsor
• Medical history of Kock pouch (ileostomy after proctocolectomy)
• Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
• Known gastrointestinal (GI) disorders (eg stomach ulcers, duodenal ulcers, GI bleeding) or inflammatory bowel disease (eg Crohn's disease, ulcerative colitis)
• Febrile illness within 1 week prior to admission to study center
• Relevant diseases within the last 4 weeks prior to admission to study center
• Known severe allergies, non-allergic drug reactions, or multiple drug allergies
• Known hypersensitivity to the study drugs (active substances or excipients of the preparations)
• Subjects with diagnosed malignancy within the past 5 years

For subjects with hepatic impairment:

• Severe cerebrovascular or cardiac disorders, e.g., myocardial infarction less than 6 months prior to dosing, congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring anti-arrhythmic treatment
• Evidence of hepatic encephalopathy related to chronic liver disease > grade 2 (exclusion by Number Connection Test (NCT))
• Subjects with percutaneous transluminal coronary angioplasty or coronary artery bypass graft less than 6 months prior to study drug administration
• History of bleeding within the past 3 months
• Thrombotic disorder
• Subjects with diabetes mellitus with a glycohemoglobin A1c (HbA1c) >10%
• Severe ascites of more than 6 L (estimated by ultrasound)
• Subjects with primary and secondary biliary cirrhosis
• Subjects with sclerosing cholangitis
• Failure of any other major organ system other than the liver
• Severe infection, malignancy, or psychosis, or any clinically significant illness within 4 weeks prior to study drug administration

For healthy subjects:

• Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal
• Subjects with conspicuous findings in medical history or pre-study examination
• A history of relevant diseases of vital organs, the central nervous system, or other organs

Contacts and Locations

Locations

Germany

Lübeck, Germany, 23538

Sponsors and Collaborators

Bayer

Merck Sharp & Dohme Corp.

Investigators

• Study Director: Bayer Study Director; Bayer

More Information

Additional Information:

Click here to find results for studies related to Bayer products 

• Responsible Party: Bayer
• ClinicalTrials.gov Identifier: NCT04722562
• Other Study ID Numbers: 15840; 2014-001206-18 ( EudraCT Number )
• First Posted: January 25, 2021
• Last Update Posted: January 25, 2021
• Last Verified: January 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Heart Failure; Heart Diseases; Cardiovascular Diseases